Clinical stage biopharmaceutical company Syndax Pharmaceuticals Inc. (SNDX:NASDAQ), which is developing an innovative pipeline of cancer therapies, today announced that "it has entered into an agreement with five leading life sciences investors, including Biotechnology Value Fund L.P., Boxer Capital and AI Life Sciences Investments LLC, an affiliate of Access Industries Inc., for the purchase of common stock at $8.00 per share, representing a premium of 20% to the share price as of market close on Thursday, January 30, 2020." The company advised that it expects the transaction to close on or around February 4, 2020, and will provide approximately $35 million in aggregate gross proceeds to the firm.
Additionally, Syndax reported that it entered into a term sheet with Hercules Capital Inc. (HTGC:NYSE) for a term loan of up to $30 million to support the company's pipeline development. The agreement states that Hercules would fund $20 million initially and allow for a potential second tranche of $10 million subject to meeting certain provisions.
The announcement came just one day after the company reported results that support ongoing Phase 1/2 AUGMENT-101 trial of Syndax its lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML. The firm made the announcement that "Science magazine has published a preclinical report titled supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML)."
Scott A. Armstrong, M.D., Ph.D., president of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, chairman of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute and senior author of the study, commented, "These unprecedented findings highlight the potential for single agent Menin-MLL inhibition to rapidly eradicate fully developed NPM1 mutant leukemia, even in the case of aggressive relapsed AML...these results provide support for a Menin-MLL inhibitor to serve as a novel strategy to prevent AML development in high-risk patient populations, as NPM1 mutations are acquired in pre-leukemic clones."
The company's CEO Briggs W. Morrison, M.D. remarked, "NPM1 mutant AML represents the most common type of cytogenetically normal AML...On the heels of our recent Cancer Cell publication, these findings add to the growing body of compelling preclinical data supporting the potential for SNDX-5613 to serve as an effective intervention for both NPM1 mutant AML and MLL-r acute leukemias. We are committed to providing patients with more targeted therapeutic options and are hopeful that these findings will translate into the clinic in our ongoing Phase 1/2 AUGMENT-101 trial."
Syndax Pharmaceuticals is headquartered in Waltham, Mass., and began the day with a market capitalization of around $180.8 million with approximately 27.14 million shares outstanding. SNDX shares opened more than 20% higher today at $8.17 (+$1.51, +22.67%) over yesterday's $6.66 closing price. The stock has traded today between $7.80 and $9.50 per share and is currently trading at $9.39 (+$2.70, +40.39%).[NLINSERT]
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.